| 2004N-0330 - Joint Meeting of the Psychopharmacologic Drugs Advisory Committee and the Pediatric Advisory Committee|
|FDA Comment Number :||EC12|
|Submitter :||Dr. Carol Tamminga||Date & Time:||08/30/2004 02:08:35|
|Organization :||American College of Neuropsychopharmacology|
|Health Care Association|
| ACNP COMMENTS ON SSRI USE IN ADOLESCENTS
Depression in youth is a serious disorder. It affects school, family and peer relationships, can lead to drug/alcohol abuse and suicide, and is recurrent, often leading to adult depression. Furthermore, depression itself impacts the developing brain. Allowing depression to go untreated significantly delays improvement, thereby increasing the likelihood of long-term negative outcomes.
(Full Comments Attached)